[{"orgOrder":0,"company":"Hackensack Meridian Health","sponsor":"Compass Pathways","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Psilocybine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Hackensack Meridian Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hackensack Meridian Health \/ Hackensack Meridian Health","highestDevelopmentStatusID":"10","companyTruncated":"Hackensack Meridian Health \/ Hackensack Meridian Health"}]

Find Clinical Drug Pipeline Developments & Deals by Hackensack Meridian Health

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : The collaboration aims to inform the delivery model design of investigational COMP360, a proprietary formulation of synthetic psilocybin, for treatment-resistant depression (TRD).

                          Brand Name : COMP360

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          January 16, 2024

                          Lead Product(s) : Psilocybine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Recipient : Compass Pathways

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank